Bal Pharma locked in an upper circuit of 20% to Rs 120.18 after the company's consolidated net profit stood at Rs 5.53 crore in Q4 FY24, steeply higher than Rs 1.61 crore in Q4 FY23.
Revenue from operations jumped 14.76% YoY to Rs 94.62 crore in Q4 FY24.Profit before tax surged to Rs 5.75 crore in Q4 FY24 from Rs 2.41 crore in Q4 FY23.
Total expenses increased 13.84% to Rs 91.32 crore in Q4 FY24 as compared with Rs 80.22 crore in Q4 FY23. Cost of material consumed stood at Rs 51.90 crore (up 2.45% YoY), employee benefit expenses was at Rs 15.63 crore (up 6.84%) and finance cost was at Rs 4.13 crore (up 7.27% YoY) during the period under review.
Meanwhile, the companys board has declared a dividend of Rs 1.20 per equity share.
Bal Pharma is a leading Indian Pharmaceutical Company with 25 years of experience, specialized in Prescription Drugs, Generic & OTC Products, Intravenous Infusion and Bulk Actives. APIs are largely exported to Europe, Far East, Latin America, Africa, Middle East and other World markets. The FDF are exported to Semi-Regulated, Non-Regulated market and are now foraying to regulated market. We are also one of the strong contenders for World Tender Business.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
